Drugena: A Fully Automated Immunoinformatics Platform for the Design of Antibody-Drug Conjugates Against Neurodegenerative Diseases

Adv Exp Med Biol. 2020;1194:203-215. doi: 10.1007/978-3-030-32622-7_18.

Abstract

Antibodies are proteins that are the first line of defense in the adaptive immune response of vertebrates. Thereby, they are involved in a multitude of biochemical mechanisms and clinical manifestations with significant medical interest, such as autoimmunity, the regulation of infection, and cancer. An emerging field in antibody science that is of huge medicinal interest is the development of novel antibody-interacting drugs. Such entities are the antibody-drug conjugates (ADCs), which are a new type of targeted therapy, which consist of an antibody linked to a payload drug. Overall, the underlying principle of ADCs is the discerning delivery of a drug to a target, hoping to increase the potency of the original drug. Drugena suite is a pioneering platform that employs state-of-the-art computational biology methods in the fight against neurodegenerative diseases using ADCs. Drugena encompasses an up-to-date structural database of specialized antibodies for neurological disorders and the NCI database with over 96 million entities for the in silico development of ADCs. The pipeline of the Drugena suite has been divided into several steps and modules that are closely related with a synergistic fashion under a user-friendly graphical user interface.

Keywords: Computational biology; Genetics; Genome engineering; Immunoinformatics; Neurodegenerative diseases; Neuropharmacology.

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Drug Design*
  • Humans
  • Immunoconjugates* / therapeutic use
  • Medical Informatics* / methods
  • Neoplasms / drug therapy
  • Neurodegenerative Diseases* / drug therapy
  • Pharmaceutical Preparations / chemistry

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • Pharmaceutical Preparations